Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00949767 | Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects | PHASE1 | COMPLETED | 64 | — | — | Jul 1, 2009 | Mar 1, 2010 | Jan 25, 2011 | 1 | Sweden |
| Arm | Type | Description |
|---|---|---|
| BMS-866949 (Panel 1) | EXPERIMENTAL | - |
| BMS-866949 (Panel 2) | EXPERIMENTAL | - |
| BMS-866949 (Panel 3) | EXPERIMENTAL | - |
| BMS-866949 (Panel 4) | EXPERIMENTAL | - |
| BMS-866949 (Panel 5) | EXPERIMENTAL | - |
| BMS-866949 (Panel 6) | EXPERIMENTAL | - |
| BMS-866949 (Panel 7) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-866949 | DRUG | (Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days |
| Placebo | DRUG | (Matching volume) - Oral Solution, Oral, once 14 days |
Inclusion Criteria: * Healthy male 18-55 * Women not of child bearing potential, 18-55 Exclusion Criteria: * History of or current treatment for psychiatric illnesses, substance abuse or dependence * History of a clinically significant neurological disorder (e.g., history of stroke, head trauma, ...